Terminated PHASE3 INTERVENTIONAL 3-arm NCT00467584

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

Sponsor: Mayo Clinic

Interventions High Dose Aspirin (1300 mg/day) Low Dose Aspirin (162 mg/day) Placebo

Updated 7 times since 2017 Last updated: May 15, 2014 Started: Jul 31, 2007 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interim analysis indicated treatment unlikely effective;slow recruitment

Other terminated trials from Mayo Clinic

See all terminations from Mayo Clinic

A PHASE3 clinical study on Fatigue and Multiple Sclerosis, this trial is terminated or withdrawn. The trial is conducted by Mayo Clinic and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic
National Multiple Sclerosis Society

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Scottsdale, United States